PI3K/PTEN/Akt Pathway

A critical mediator of oncogenic signaling
  • Juan Paez
  • William R. Sellers
Part of the Cancer Treatment and Research book series (CTAR, volume 115)


In conclusion, direct genetic alterations leading to deregulated PI3K/Akt signalling are common in a significant fraction of human malignancies. The forthcoming decade should witness the development and clinical deployment of a number of novel small molecule inhibitors specifically designed to disrupt the function of members of this pathway. It is hoped and perhaps likely that such inhibitors, either alone or in combination with current therapeutics, will ultimately proof clinically efficacious.


Focal Adhesion Kinase PTEN Gene Pleckstrin Homology Domain PTEN Mutation PTEN Loss 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adey, N. B., Huang, L., Ormonde, P. A., Baumgard, M. L., Pero, R., Byreddy, D. V., Tavtigian, S. V., & Bartel, P. L. (2000). Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res, 60(1), 35–37.PubMedGoogle Scholar
  2. Ali, I. U., Schriml, L. M., & Dean, M. (1999). Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst, 91(22), 1922–1932.CrossRefPubMedGoogle Scholar
  3. Altiok, S., Batt, D., Altiok, N., Papautsky, A., Downward, J., Roberts, T. M., & Avraham, H. (1999). Here gulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT inbreast cancer cells. J Biol Chem, 274(45), 32274–32278.CrossRefPubMedGoogle Scholar
  4. Aoki, M., Batista, O., Bellacosa, A., Tsichlis, P., & Vogt, P. K. (1998). The akt kinase; molecular determinants of oncogenicity. Proc Natl Acad Sci USA, 95(25), 14950–14955.CrossRefPubMedGoogle Scholar
  5. Aoki, M., Blazek, E., & Vogt, P. K. (2001). A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA, 98(1), 136–141.CrossRefPubMedGoogle Scholar
  6. Aoki, M., Schetter, C., Himly, M., Batista, O., Chang, H. W., & Vogt, P. K. (2000). The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem, 275(9), 6267–6275.CrossRefPubMedGoogle Scholar
  7. Ayton, P. M, & Cleary, M. L. (2001). Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene, 20(40), 5695–5707.CrossRefPubMedGoogle Scholar
  8. Backman, S. A., Stambolic, V., Suzuki, A., Haight, J., Elia, A., Pretorius, J., Tsao, M. S., Shannon, P., Bolon, B., Ivy, G. O., & Mak, T. W. (2001). Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet, 29(4), 396–403.CrossRefPubMedGoogle Scholar
  9. Balendran, A., Casamayor, A., Deak, M., Paterson, A., Gaffney, P., Currie, R., Downes, C. P., & Alessi, D. R. (1999). PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. CurrBiol, 9(8), 393–404.Google Scholar
  10. Barlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y., Bittner, M. L., Torhorst, J., Haas, P., Bucher, C., Sauter, G., Kallioniemi, O. P., & Kallioniemi, A. (2000). Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst, 92(15), 1252–1259.CrossRefPubMedGoogle Scholar
  11. Barr, F. G. (2001). Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene, 20(40), 5736–5746.CrossRefPubMedGoogle Scholar
  12. Basso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002). Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene, 21(8), 1159–1166.CrossRefPubMedGoogle Scholar
  13. Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., & et at. (1995). Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer, 64(4), 280–285.PubMedGoogle Scholar
  14. Bellacosa, A., Testa, J. R., Staal, S. P., & Tsichlis, P. N. (1991). A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science, 254(5029), 274–277.PubMedGoogle Scholar
  15. Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A., & Nussbaum, R. L. (1999), Proliferative defect and embryonic lethality in mice homozygous for a deletion in the pl10alpha subunit of phosphoinositide 3-kinase. J Biol Chem, 274(16), 10963–10968.CrossRefPubMedGoogle Scholar
  16. Biggs, W. H., 3rd, Meisenhelder, J., Hunter, T., Cavenee, W. K., & Arden, K. C. (1999). Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA, 96(13), 7421–7426.CrossRefPubMedGoogle Scholar
  17. Bonneau, D., & Longy, M. (2000). Mutations of the human PTEN gene. Hum Mutat, 16(2), 109–122.CrossRefPubMedGoogle Scholar
  18. Borkhardt, A., Repp, R., Haas, O. A., Leis, T., Harbott, J., Kreuder, J., Hammermann, J., Henn, T., & Lamport, F. (1997). Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;ll)(ql3;q23). Oncogene, 14(2), 195–202.CrossRefPubMedGoogle Scholar
  19. Bostrom, J., Cobbers, J. M., Wolter, M., Tabatabai, G., Weber, R. G., Lichter, P., Collins, V. P., & Reifenberger, G. (1998). Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res, 58(1), 29–33.PubMedGoogle Scholar
  20. Brogiolo, W., Stacker, H., Ikeya, T., Rintelen, F., Fernandez, R., & Hafen, E. (2001). An evolutionary conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol, 11(4), 213–221.CrossRefPubMedGoogle Scholar
  21. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96(6), 857–868.CrossRefPubMedGoogle Scholar
  22. Brunet, A., Kanai, F., Stehn, J., Xu, J., Sarbassova, D., Frangioni, J. V., Dalal, S. N., DeCaprio, J. A., Greenberg, M. E., & Yaffe, M. B. (2002). 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol, 156(5), 817–828.CrossRefPubMedGoogle Scholar
  23. Cantley, L. C., & Neel, B. G. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA, 96(8), 4240–4245.CrossRefPubMedGoogle Scholar
  24. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998). Regulation of cell death protease caspase-9 by phosphorylation. Science, 282(5392), 1318–1321.CrossRefPubMedGoogle Scholar
  25. Carpenter, C. L., Duckworth, B. C., Auger, K. R., Cohen, B., Schaffhausen, B. S., & Cantley, L. C. (1990). Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem, 265(32), 19704–19711.PubMedGoogle Scholar
  26. Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Bellacosa, A., Tsichlis, P. N., Cantley, L. C., Roberts, T. M., & Vogt, P. K. (1997). Transformation of chicken cells by the gene encoding the catalylic subunit of PI 3-kinase. Science, 276(5320), 1848–1850.CrossRefPubMedGoogle Scholar
  27. Chen, W. S., Xu, P. Z., Gottlob, K., Chen, M. L., Sokol, K., Shiyanova, T., Roninson, I., Weng, W., Suzuki, R., Tobe, K., Kadowaki, T., & Hay, N. (2001). Growth retardation and increased apoptosis in mice with homozygous disruption of the Aktl gene. Genes Dev, 15(17), 2203–2208.CrossRefPubMedGoogle Scholar
  28. Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J, R. (1992), AKT2, a putative oncogene encoding a member of a subfamily of proteinserine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA, 89(19), 9267–9271.PubMedGoogle Scholar
  29. Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D, A., Watson, D. K., & Testa, J. R (1996), Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA, 93(8), 3636–3641.CrossRefPubMedGoogle Scholar
  30. Chiosis, G., Rosen, N., & Sepp-Lorenzino, L. (2001). LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett, 11(7), 909–913.CrossRefPubMedGoogle Scholar
  31. Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., 3rd, Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., & Birnbaum, M. J. (2001). Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science, 292(5522), 1728–1731.CrossRefPubMedGoogle Scholar
  32. Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F., & Birnbaum, M. J. (2001). Aktl/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem, 276(42), 38349–38352.CrossRefPubMedGoogle Scholar
  33. Coffer, P. J., Jin, J., & Woodgett, J. R. (1998). Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J, 335(Pt 1), 1–13.PubMedGoogle Scholar
  34. Datta, S. R., Brunet, A., & Greenberg, M. E. (1999). Cellular survival: a play in three Akts. Genes Dev, 13(22), 2905–2927.CrossRefPubMedGoogle Scholar
  35. Dedhar, S., Williams, B., & Hannigan, G. (1999). Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol, 9(8), 319–323.CrossRefPubMedGoogle Scholar
  36. del Peso, L., Gonzalez, V. M., Hernandez, R., Barr, F. G., & Nunez, G. (1999). Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene, 18(51), 7328–7333.PubMedGoogle Scholar
  37. Dennis, P. B., Jaeschke, A., Saitoh, M., Fowler, B., Kozma, S. C., & Thomas, G, (2001). Mammalian TOR: a homeostatic ATP sensor. Science, 294(5544), 1102–1105.CrossRefPubMedGoogle Scholar
  38. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998). Pten is essential for embryonic development and tumour suppression. Nat Genet, 19(4), 348–355.PubMedGoogle Scholar
  39. Dijkers, P. P., Medema, R. H., Lammers, J. W., Koenderman, L., & Coffer, P. J. (2000). Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol, 10(19), 1201–1204.CrossRefPubMedGoogle Scholar
  40. Downward, J. (1998). Ras signalling and apoptosis. Curr Opin Genet Dev, 8(1), 49–54.CrossRefPubMedGoogle Scholar
  41. Duerr, E. M., Rollbrocker, B., Hayashi, Y., Peters, N., Meyer-Puttlitz, B., Louis, D. N., Schramm, J., Wiestler, O. D., Parsons, R., Eng, C., & von Deimling, A. (1998). PTEN mutations in gliomas and glioneuronal tumors. Oncogene, 16(17), 2259–2264.CrossRefPubMedGoogle Scholar
  42. Eng, C, Murday, V., Seal, S., Mohammed, S., Hodgson, S. V., Chaudary, M. A., Fentiman, I. S., Ponder, B. A., & Eeles, R. A. (1994). Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy? J Med Genet, 31(6), 458–461.PubMedGoogle Scholar
  43. Franke, T. F., Kaplan, D. R., Cantley, L. C., & Toker, A. (1997). Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science, 275(5300), 665–668.CrossRefPubMedGoogle Scholar
  44. Franklin, S., Pho, T., Abreo, F. W., Nassar, R., De Benedetti, A., Stacker, F. J., & Nathan, C. A. (1999). Detection of theproto-oncogene eIF4E in larynx and hypopharynx cancers. Arch Otolaryngol Head Neck Surg, 125(2), 177–182.PubMedGoogle Scholar
  45. Fredericks, W. J., Galili, N., Mukhopadhyay, S., Rovera, G., Bennicelli, J., Barr, F. G., & Rauscher, F. J., 3rd. (1995). The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol, 15(3), 1522–1535.PubMedGoogle Scholar
  46. Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998). Phosphoinositide kinases. Annu Rev Biochem, 67, 481–507.CrossRefPubMedGoogle Scholar
  47. Furnari, F. B., Huang, H. J., & Cavenee, W. K. (1998). The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glionia cells. Cancer Res, 58(22), 5002–5008PubMedGoogle Scholar
  48. Galetic, I., Andjelkovic, M., Meier, R., Brodbeck, D., Park, J., & Hemmings, B. A. (1999). Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase-significance for diabetes and cancer. Pharmacol Ther, 82(2–3), 409–425.PubMedGoogle Scholar
  49. Georgescu, M. M., Kirsch, K. H., Kaloudis, P., Yang, H., Pavletich, N. P., & Hanafusa, H. (2000). Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res, 60(24), 7033–7038PubMedGoogle Scholar
  50. Gingras, A, C., Raught, B., & Sonenberg, N. (2001). Regulation of translation initiation by FRAP/mTOR, Genes Dev, 15(7), 807–826.CrossRefPubMedGoogle Scholar
  51. Goberdhan, D. C., Paricio, N., Goodman, E. C, Mlodzik, M., & Wilson, C. (1999). Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev, 13(24), 3244–3258.CrossRefPubMedGoogle Scholar
  52. Gu, J., Tamura, M., Pankov, R., Danen, E. H., Takino, T., Matsumoto, K., & Yamada, K. M. (1999). Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol, 146(2), 389–403.CrossRefPubMedGoogle Scholar
  53. Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K. W., & Geissler, E. K. (2002). Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med, 8(2), 128–135.CrossRefPubMedGoogle Scholar
  54. Guldberg, P., thor Straten, P., Birck, A., Ahrenkiel, V., Kirkin, A. F., & Zeuthen, J. (1997). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res, 57(17), 3660–3663.PubMedGoogle Scholar
  55. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70.CrossRefPubMedGoogle Scholar
  56. Healy, E., Belgaid, C., Takata, M., Harrison, D., Zhu, N. W., Burd, D. A., Rigby, H. S., Matthews, J.N., & Rees, J. L. (1998). Prognostic significance of allelic losses in primary melanoma. Oncogene, 16(17), 2213–2218.CrossRefPubMedGoogle Scholar
  57. Hillion, J., Le Coniat, M., Jonveaux, P., Berger, R., & Bernard, O. A, (1997). AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood, 90(9), 3714–3719.PubMedGoogle Scholar
  58. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., & Jaffe, R. B. (2002), Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res, 62(4), 1087–1092.PubMedGoogle Scholar
  59. Huang, H., Potter, C. J., Tao, W., Li, D. M,, Brogiolo, W., Hafen, E., Sun, H., & Xu, T. (1999). PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development. Development, 126(23), 5365–5372.PubMedGoogle Scholar
  60. Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R., & Muller, W. J. (2001). Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol, 21(6), 2203–2212.CrossRefPubMedGoogle Scholar
  61. Isshiki, K., Elder, D. E., Guerry, D., & Linnenbach, A. J. (1993). Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer, 8(3), 178–184.PubMedGoogle Scholar
  62. Kandel, E, S., & Hay, N. (1999). The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res, 253(1), 210–229.CrossRefPubMedGoogle Scholar
  63. Kane, L. P., Shapiro, V. S., Stokoe, D., & Weiss, A. (1999). Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol, 9(11), 601–604.CrossRefPubMedGoogle Scholar
  64. Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer, Annu Rev Cell Dev Biol, 17, 615–675.CrossRefPubMedGoogle Scholar
  65. Khwaja, A. (1999). Akt is more than just a Bad kinase. Natuae, 401(6748), 33–34.Google Scholar
  66. Klippel, A., Escobedo, M. A., Wachowicz, M. S., Apell, G., Brown, T. W., Giedlin, M. A., Kavanaugh, W. M., & Williams, L. T. (1998). Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol. 18(10), 5699–5711.PubMedGoogle Scholar
  67. Konishi, H., Kuroda, S., Tanaka, M., Matsuzaki, H., Ono, Y., Kameyama, K., Haga, T., & Kikkawa, U. (1995). Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun, 216(2), 526–534.CrossRefPubMedGoogle Scholar
  68. Kops, G. J., & Burgering, B. M, (1999). Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med, 77(9), 656–665.CrossRefPubMedGoogle Scholar
  69. Kops, G. J., de Ruiter, N. D., De Vries-Smits, A. M., Powell, D. R., Bos, J. L., & Burgering, B. M. (1999). Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature, 398(6728), 630–634.PubMedGoogle Scholar
  70. Kotani, K., Hara, K., Yonezawa, K., & Kasuga, M. (1995). Phosphoinositide 3-kinase as an upstream regulator of the small GTP-binding protein Rac in the insulin signaling of membrane ruffling. Biochem Biophys Res Commun, 208(3), 985–990.CrossRefPubMedGoogle Scholar
  71. Kuruvilla, F. G., & Schreiber, S. L. (1999). The PIK-related kinases intercept conventional signaling pathways. Chem Biol, 6(5), R129–136.CrossRefPubMedGoogle Scholar
  72. Kwon, C. H., Zhu, X., Zhang, J., Knoop, L. L., Tharp, R., Smeyne, R. J., Eberhart, C. G., Burger, P. C., & Baker, S. J. (2001). Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet, 29(4), 404–411.CrossRefPubMedGoogle Scholar
  73. Lee, J. O., Yang, H., Georgescu, M. M., Di Cristofano, A., Maehama, T., Shi, Y., Dixon, J. E., Pandolfi, P., & Pavletich, N. P. (1999). Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell, 99(3), 323–334.PubMedGoogle Scholar
  74. Levine, R. L., Cargile, C. B., Blazes, M. S., van Rees, B., Kurman, R. J., & Ellenson, L. H. (1998). PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res, 58(15), 3254–3258.PubMedGoogle Scholar
  75. Li, D, M., & Sun, H. (1997). TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res, 57(11), 2124–2129.PubMedGoogle Scholar
  76. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., & Parsons, R. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275(5308), 1943–1947.CrossRefPubMedGoogle Scholar
  77. Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacocke, M., Eng, C., & Parsons, R. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet, 16(1), 64–67.CrossRefPubMedGoogle Scholar
  78. Lin, K., Dorman, J. B., Rodan, A., & Kenyon, C. (1997). daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science, 278(5341), 1319–1322.CrossRefPubMedGoogle Scholar
  79. Liu, W., James, C. D., Frederick, L., Alderete, B. E., & Jenkins, R. B. (1997). PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res, 57(23), 5254–5257.PubMedGoogle Scholar
  80. Ma, Y. Y., Wei, S. J., Lin, Y. C., Lung, J. C., Chang, T. C., Whang-Peng, J., Liu, J. M., Yang, D. M., Yang, W. K., & Shen, C. Y. (2000). PIK3CA as an oncogene in cervical cancer. Oncogene, 19(23), 2739–2744.CrossRefPubMedGoogle Scholar
  81. Maehama, T., & Dixon, J. E. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem, 273(22), 13375–13378.CrossRefPubMedGoogle Scholar
  82. Maehama, T., Taylor, G. S., & Dixon, J. E. (2001). PTEN AND MYOTUBULARIN: Novel Phosphoinositide Phosphatases. Annu Rev Biochem, 70, 247–279.CrossRefPubMedGoogle Scholar
  83. Maxwell, G. L., Risinger, J. I., Gumbs, C., Shaw, H., Bentley, R. C., Barrett, J. C., Berchuck, A., & Futreal, P. A. (1998). Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res, 58(12), 2500–2503.PubMedGoogle Scholar
  84. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M., & Sellers, W. R. (1999). Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res, 59(17), 4291–4296.PubMedGoogle Scholar
  85. Medema, R. H., Kops, G. J., Bos, J. L., & Burgering, B. M. (2000). AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kipl. Nature, 404(6779), 782–787.PubMedGoogle Scholar
  86. Mende, I., Malstrom, S., Tsichlis, P. N., Vogt, P. K., & Aoki, M. (2001). Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene, 20(32), 4419–4423.CrossRefPubMedGoogle Scholar
  87. Montagnani, M., Chen, H., Barr, V. A., & Quon, M. J. (2001). Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem, 276(32), 30392–30398.CrossRefPubMedGoogle Scholar
  88. Munster, P. N., Basso, A., Solit, D., Norton, L., & Rosen, N. (2001). Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-inducedapoptosis in an RB-and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155–2158, 2001, Clin Cancer Res, 7(8), 2228–2236.PubMedGoogle Scholar
  89. Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., & Tonks, N. K. (1998). The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Set USA, 95(23), 13513–13518.Google Scholar
  90. Myers, M. P., & Tonks, N. K. (1997). PTEN: sometimes taking it off can be better than putting it on. Am J Hum Genet, 61(6), 1234–1238.CrossRefPubMedGoogle Scholar
  91. Nakamura, N., Ramaswamy, S., Vazquez, F., Signoretti, S., Loda, M., & Sellers, W. R. (2000). Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol, 20(23), 8969–8982.CrossRefPubMedGoogle Scholar
  92. Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., & Roth, R. A. (1999). Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem, 274(31), 21528–21532.CrossRefPubMedGoogle Scholar
  93. Nelen, M. R., van Staveren, W. C., Peeters, E. A., Hassel, M. B., Gorlin, R. J., Hamm, H., Lindboe, C. F., Fryns, J. P., Sijmons, R, H., Woods, D. G., Mariman, E. C., Padberg, G. W., & Kremer, H. (1997). Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet, 6(8), 1383–1387.CrossRefPubMedGoogle Scholar
  94. Neshat, M, S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001). Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA, 98(18), 10314–10319.CrossRefPubMedGoogle Scholar
  95. Obata, K., Morland, S, J., Watson, R. H,, Hitchcock, A., Chenevix-Trench, G., Thomas, E. J., & Campbell, I. G. (1998). Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res, 58(10), 2095–2097.PubMedGoogle Scholar
  96. Ogg, S., & Ruvkun, G. (1998). The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol Cell, 2(6), 887–893.CrossRefPubMedGoogle Scholar
  97. Okano, J., Gaslightwala, I., Birnbaum, M. J., Rustgi, A. K., & Nakagawa, H. (2000). Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem, 275(40), 30934–30942.CrossRefPubMedGoogle Scholar
  98. Oldham, S., Bohni, R., Stocker, H., Brogiolo, W., & Hafen, E. (2000), Genetic control of size in Drosophila. Philos Trans R Soc Lond B Biol Sci, 355(1399), 945–952.PubMedGoogle Scholar
  99. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999). NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401(6748), 82–85.PubMedGoogle Scholar
  100. Pece, S., Chiariello, M., Murga, C., & Gutkind, J. S. (1999). Activation of the protein kinase Akt/PKB by the formation of E-cadherin-mediated cell-cell junctions. Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex. J Biol Chem, 274(27), 19347–19351.CrossRefPubMedGoogle Scholar
  101. Peng, H., Kim, D. I., Sarkaria, J. N., Cho, Y. S., Abraham, R. T., & Zalkow, L. H. (2002). Novel pyrrolo-quinoline derivatives as potent inhibitors for PI3-kinase related kinases. Bioorg Med Chem, 10(1), 167–174.PubMedGoogle Scholar
  102. Persad, S., Attwell, S., Gray, V., Mawji, N., Deng, J. T., Leung, D., Yan, J., Sanghera, J., Walsh, M. P., & Dedhar, S. (2001). Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem, 276(29), 27462–27469.CrossRefPubMedGoogle Scholar
  103. Phillips, W. A., St Clair, F., Munday, A. D., Thomas, R. J., & Mitchell, C. A. (1998). Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer, 83(1), 41–47.CrossRefPubMedGoogle Scholar
  104. Philp, A. J., Campbell, I. G., Leet, C., Vincan, E., Rockman, S. P., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001). The phosphatidylinositol 3’-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res, 61(20), 7426–7429.PubMedGoogle Scholar
  105. Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., & Parsons, R. (1999). Mutation of Pten/Mmacl in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA, 96(4), 1563–1568.CrossRefPubMedGoogle Scholar
  106. Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., Frost, P., Dreisbach, V., Blenis, J., Gaciong, Z., Fisher, P., Sawyers, C., Hedrick-Ellenson, L., & Parsons, R. (2001). An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc Natl Acad Sci USA, 98(18), 10320–10325.CrossRefPubMedGoogle Scholar
  107. Posern, G., Saffrich, R., Ansorge, W., & Feller, S. M. (2000). Rapid lamellipodia formation in nerve growth factor-stimulated PC12 cells is dependent on Rac and PI3K activity. J Cell Physiol, 183(3), 416–424CrossRefPubMedGoogle Scholar
  108. Ramaswamy, S., Nakamura, N., Vazquez, F., Batt, D. B., Perera, S., Roberts, T. M., & Sellers, W. R. (1999). Regulation of Gl progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinosito) 3-kinase/Akt pathway. Proc Natl Acad Sci USA, 96(5), 2110–2115.CrossRefPubMedGoogle Scholar
  109. Rasheed, B. K., Stenzel, T. T., McLendon, R. E., Parsons, R., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Bigner, S. H. (1997). PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res, 57(19), 4187–4190.PubMedGoogle Scholar
  110. Rasheed, B. K., Wiltshire, R. N., Bigner, S. H., & Bigner, D. D. (1999). Molecular pathogenesis of malignant gliomas. Curr Opin Oncol, 11(3), 162–167.PubMedGoogle Scholar
  111. Rena, G., Guo, S., Cichy, S. C., Unterman, T. G., & Cohen, P. (1999). Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem, 274(24), 17179–17183.CrossRefPubMedGoogle Scholar
  112. Romashkova, J. A., & Makarov, S. S. (1999). NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 401(6749), 86–90PubMedGoogle Scholar
  113. Sausville, E. A. (2001). Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Munster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB-and schedule-dependent manner. Clin. Cancer Res., 7: 2228–2236, 2001. Clin Cancer Res, 7(8), 2155–2158.Google Scholar
  114. Schneider, C., Sepp-Lorenzino, L., Nimmesgern, E., Ouerfelli, O., Danishefsky, S., Rosen, N., & Hartl, F. U. (1996). Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci USA, 93(25), 14536–14541.CrossRefPubMedGoogle Scholar
  115. Shaw, L. M., Rabinovitz, I., Wang, H. H., Toker, A., & Mercurio, A. M. (1997). Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell, 91(7), 949–960.CrossRefPubMedGoogle Scholar
  116. Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999). PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet, 21(1), 99–102.CrossRefPubMedGoogle Scholar
  117. Simpson, L., & Parsons, R. (2001). PTEN: life as a tumor suppressor. Exp Cell Res, 264(1), 29–41.CrossRefPubMedGoogle Scholar
  118. Somerville, R. P., Shoshan, Y., Eng, C., Barnett, G., Miller, D., & Cowell, J. K. (1998). Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been Implicated in glioblastoma multiforme disease progression. Oncogene, 17(13), 1755–1757.CrossRefPubMedGoogle Scholar
  119. Staal, S. P. (1987). Molecular cloning of the akt oncogene and its humanhomologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA, 84(14), 5034–5037.PubMedGoogle Scholar
  120. Staal, S. P., & Hartley, J. W. (1988). Thymic lymphoma induction by the AKT8 murine retrovirus. J Exp Med, 167(3), 1259–1264.CrossRefPubMedGoogle Scholar
  121. Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C, Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95(1), 29–39.CrossRefPubMedGoogle Scholar
  122. Stambolic, V., Tsao, M. S., Macpherson, D., Suzuki, A., Chapman, W. B., & Mak, T. W. (2000). High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice. Cancer Res, 60(13), 3605–3611.PubMedGoogle Scholar
  123. Steck, P. A., Lin, H., Langford, L. A., Jasser, S. A., Koul, D., Yung, W. K., & Pershouse, M. A. (1999). Functional and molecular analyses of l0q deletions in human gliomas. Genes Chromosomes Cancer, 24(2), 135–143.CrossRefPubMedGoogle Scholar
  124. Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H., & Tavtigian, S. V. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 15(4), 356–362.CrossRefPubMedGoogle Scholar
  125. Stein, R. C., & Waterfield, M. D. (2000). PI3-kinase inhibition: a target for drug development? Mol Med Today, 6(9), 347–357.PubMedGoogle Scholar
  126. Stocker, H., Andjelkovio, M., Oldham, S., Laffargue, M., Wymann, M. P., Hemmings, B. A., & Hafen, E. (2002). Living with Lethal PIPS Levels: Viability of Flies Lacking PTEN Restored by a PH Domain Mutation in Akt/PKB. Science.Google Scholar
  127. Sun, H., Lesche, R., Li, D. M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., & Wu, H. (1999). PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway, Proc Natl Acad Sci USA, 96(11), 6199–6204.CrossRefPubMedGoogle Scholar
  128. Sun, M., Wang, G., Paciga, J. E., Feldman, R. L, Yuan, Z. Q., Ma, X. L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., & Cheng, J. Q. (2001). AKTl/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol, 159(2), 431–437.PubMedGoogle Scholar
  129. Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., del Barco Barrantes, I., Ho, A., Wakeham, A., Itie, A., Khoo, W., Fukumoto, M., & Mak, T. W. (1998). High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol, 8(21), 1169–1178.CrossRefPubMedGoogle Scholar
  130. Tamura, M., Gu, J., Danen, E. H., Takino, T., Miyamoto, S., & Yamada, K. M. (1999). PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem, 274(29), 20693–20703.CrossRefPubMedGoogle Scholar
  131. Tamura, M., Gu, J., Matsumoto, K., Aota, S., Parsons, R., & Yamada, K. M. (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 280(5369), 1614–1617.CrossRefPubMedGoogle Scholar
  132. Tolkacheva, T., Boddapati, M., Sanfiz, A., Tsuchida, K., Kimmelman, A. C, & Chan, A. M. (2001). Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res, 61(13), 4985–4989.PubMedGoogle Scholar
  133. Tsao, H., Zhang, X., Benoit, E., & Haluska, F. G. (1998). Identification of PTEN/MMAC1 alterationsn uncultured melanomas and melanoma cell lines. Oncogene, 16(26), 3397–3402CrossRefPubMedGoogle Scholar
  134. Vanhaesebroeck, B., & Waterfield, M. D. (1999). Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res, 253(1), 239–254.CrossRefPubMedGoogle Scholar
  135. Vazquez, F., Grossman, S. R., Takahashi, Y., Rokas, M. V., Nakamura, N., & Sellers, W, R. (2001). Phosphorylation of the PTEN Tail Acts as an Inhibitory Switch by Preventing Its Recruitment into a Protein Complex. J Biol Chem, 276(52), 48627–48630.CrossRefPubMedGoogle Scholar
  136. Vazquez, F., Ramaswamy, S., Nakamura, N., & Sellers, W. R. (2000). Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol, 20(14), 5010–5018.CrossRefPubMedGoogle Scholar
  137. Vazquez, F., & Sellers, W. R. (2000). The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta, 1470(1), M21–35.Google Scholar
  138. Verdu, J., Buratovich, M. A., Wilder, E. L, & Birnbaum, M. J. (1999). Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat Cell Biol, 1(8), 500–506.CrossRefPubMedGoogle Scholar
  139. Wang, S. I., Puc, J., Li, J., Bruce, J. N., Cairns, P., Sidransky, D., & Parsons, R. (1997). Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res, 57(19), 4183–4186.PubMedGoogle Scholar
  140. Wu, X., Hepner, K., Castelino-Prabhu, S., Do, D., Kaye, M. B., Yuan, X. J., Wood, J., Ross, C., Sawyers, C. L., & Whang, Y. E. (2000). Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci USA, 97(8), 4233–4238.CrossRefPubMedGoogle Scholar
  141. Xu, W., Mimnaugh, E., Rosser, M. F., Nicchitta, C., Marcu, M., Yarden, Y., & Neckers, L. (2001). Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem, 276(5), 3702–3708.CrossRefPubMedGoogle Scholar
  142. Yaffe, M. B., Leparc, G. G., Lai, J., Obata, T., Volinia, S., & Cantley, L. C. (2001). A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nat Biotechnol, 19(4), 348–353CrossRefPubMedGoogle Scholar
  143. Yaffe, M. B., Rittinger, K., Volinia, S., Caron, P. R., Aitken, A., Leffers, H., Gamblin, S. J., Smerdon, S. J., & Cantley, L. C. (1997). The structural basis for 14-3-3:phosphopeptide binding specificity. Cell, 91(7), 961–971.CrossRefPubMedGoogle Scholar
  144. Yao, R., & Cooper, G. M. (1995). Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science, 267(5206), 2003–2006.PubMedGoogle Scholar
  145. Yokomizo, A., Tindall, D. J., Hartmann, L., Jenkins, R. B., Smith, D. I., & Liu, W. (1998). Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer. Int J Oncol, 13(1), 101–105.PubMedGoogle Scholar
  146. Yuan, Z. Q., Sun, M., Feldman, R. I., Wang, G., Ma, X., Jiang, C., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2000). Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene, 19(19), 2324–2330.CrossRefPubMedGoogle Scholar
  147. Zhang, H., Stallock, J. P., Ng, J. C., Reinhard, C., & Neufeld, T. P. (2000). Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev, 14(21), 2712–2724.CrossRefPubMedGoogle Scholar
  148. Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M. H., & Hung, M. C. (2001). Cytoplasmic localization of p21Cipl/WAFl by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol, 3(3), 245–252.CrossRefPubMedGoogle Scholar
  149. Zimmermann, S., & Moelling K. (1999). Phosphorylation and regulation of Raf by Akt (protein kinase B). Science, 286(5445), 1741–1744.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Juan Paez
    • 1
    • 2
  • William R. Sellers
    • 1
    • 2
  1. 1.Department of Adult Oncology Dana-Farber Cancer InstituteHarvard Medical SchoolBoston
  2. 2.Department of Medicine Brigham and Women’s HospitalHarvard Medical SchoolBoston

Personalised recommendations